Journal of Pharmacy Technology: Official Publication of the Association of Pharmacy Technicians January-December 1992: Vol 8 Index

7 Pages·2.9 MB·English

INDEX, the journal of Pharmacy Technology
VOLUME EIGHT — JANUARY THROUGH DecemsBer 1992
January/February Pages 1-48 July/August Pages 145-184
March/April Pages 49-96 September/October Pages 185-232
May/June Pages 97-144 November/December Pages 233-298
Safety Surveillance: An Industry Perspective, Asthma, peak-flow meter available (WN) 93
A-B Part I: Information Flow, New Drug Devel- Atenolol, compared with heparin in myocardial
opment, and Federal Regulations (A) 162; infarction (A) 107; in hypertension (FL) 41
Abate, Marie A. (author) book review, 4 Part II: Product Labeling and Product Atropine, in cardiac arrest (A) 153
Abbott to Market New Oral Antibiotic (WN) 44 Knowledge (A) 198; Part III: Managing Ad- Author guidelines, JF-ifc, MA ifc, MJ-ifc, JA-ifc,
ACA Endorses Joint Statement on Entry-Level verse-Event Data (A) 259 SO-ifc, ND-ifc
PharmD Degree (PF) 174 Alprazolam, use in nursing facility residents Automated Medication Storage and Dispensing
Acebutolol, in hypertension (FL) 41 (PF) 36 System (WN) 93
Acetophenazine, use in nursing facility resi- Alzheimer’s disease, unrecognized by many Azathioprine, cost and effectiveness in im-
dents (PF) 37 Americans (FL) 175 munosuppression (A) 81
Achieving Teamwork Between Pharmacists and Amantadine, adverse effects in elderly patients Azlocillin, total parenteral nutrition (A) 16
Technicians: A Pharmacist’s Perspective (FL) (A) 74 Aztreonam, total parenteral nutrition (A) 16
217 Ambroziak, Ellen M. (coauthor) see Hudson, Banakar, Umesh V. (coauthor) see Hilleman,
Adams, Diane (coauthor) see Hotta, S. Steven, Teresa J., 195 Daniel E., 203; see Mohler, Pamela A., 6
252 American Association of Colleges of Pharmacy, Barbiturates, use in nursing facility residents
Additives, contamination (A) 195; incompatibili- Scope of Pharmacy Practice Project (PF) 38 (PF) 37
ty with drugs added to total parenteral nutri- American Pharmaceutical Association, annual Bardas, Sandra L. (author) Demystifying the
tion (A) 15 meeting attendees (PF) 38; comments on ter- Cardiopulmonary Code Team Response (A)
Adherence, clinic (A) 242; see also compliance fenadine warning (PF) 216; considers techni- 151
Administration, pharmacy-based program (FL) cian recognition (PF) 130; Foundation’s an- Bartelink, Anton K.M. (coauthor) see de Valk,
278 nual meeting (PF) 174; National Pharmacists’ Harold W., 155
Adverse effects, associated with amantadine Compensation Survey (PF) 37; Scope of Bendroflumethiazide, in hypertension (FL)
(A) 74; federal regulations for reporting (A) Pharmacy Practice Project (PF) 38; to study 41
165; managing data (A) 259 medication underuse (PF) 130 Benign prostatic hyperplasia, finasteride ap-
AIDS, FDA gives 566C80 treatment IND status American Society of Consultant Pharmacists, Er- proved (WN) 226
(WN) 43; high school students at risk (FL) win receives Archambault award (WN) 43; Benzodiazepines, abuse by elderly patients (A)
220; rapid test developed (WN) 182; “under- founder dies (PF) 275 68; classification under Controlled Sub-
ground” pharmacies (FL) 219; zalcitabine ap- American Society of Hospital Pharmacists, stances Act (U) 183; use in nursing facility
proved (WN) 225 Scope of Pharmacy Practice Project (PF) 38 residents (PF) 36
Albumin, guidelines for use (A) 125; total par- Amikacin, total parenteral nutrition (A) 16 Benzthiazide, in hypertension (FL) 41
enteral nutrition (A) 14 Amiloride, in hypertension (FL) 41 Berger, Bruce A. (coauthor) see Allan, Elizabeth
Albumin Audit Results and Guidelines for Use Amino acids, total parenteral nutrition (A) 8 L., 242
(A) 125 Aminophylline, total parenteral nutrition (A) 15 Beta-blockers, in hypertension (FL) 41
Albuterol, in cardiac arrest (A) 153 Aminopropylidene diphosphonate, use in hy- Betaxolol, in hypertension (FL) 41
Alcohol, abuse by elderly patients (A) 68 percalcemia in hyperparathyroidism (A) 155 Biological safety cabinets, decontamination (U)
Aldesieukin, licensed by FDA (FL) 218 Amobarbital, use in nursing facility residents 231
Allan, Elizabeth L. (author) Patient Treatment (PF) 37 Bleske, Barry E. (author) Variability in Drug
Adherence: Facility Design and Counseling Amphotericin B, total parenteral nutrition (A) Administration Times Among Patients with
Skills (A) 242 15 Coronary Artery Disease (A) 191
Allan, Marjorie C. (author) A Primer of Drug Ampicillin, total parenteral nutrition (A) 15 Book Reviews, see Publications, New
Analysis of Adverse Effects During Amantadine Books Received, 4, 54, 104, 150, 190, 237
Prophylaxis in a Nursing Home Population Boyd, Eddie L. (coauthor) see Bleske, Barry E.,
(A) 74 191
INDEX ABBREVIATIONS Anemia, identification (U) 290 Bretylium, in cardiac arrest (A) 153
Angiotensin-converting enzyme inhibitors, dan- British Association of Pharmacy Technicians,
Article gerous in pregnant women (FL) 178; for hy- annual conference highlights (PF) 215; ori-
Editorial pertension (FL) 41 gins and goals (PF) 215
From the Literature Antibiotics, compatibility with total parenteral Brumbaugh, Brenda M. (author) Decontamina-
Inside back cover nutrition (A) 16; prescribing (A) 27 tion of a Biological Safety Cabinet (U) 231
Are Regulations That Sanction Techs Checking Bumetanide, in hypertension (FL) 41
Inside front cover
Techs Coming Soon? (PF) 276 Buspirone, use in nursing facility residents (PF)
Letters ASCP Names Erwin to Receive Archambault 36
New Publications Award (WN) 43 Busulfan, for chronic myelogenous leukemia
Pharmacy Focus inase, for acute lymphocytic leukemia (FL) 278
FoFcr2Rkm eU pdating Your Skills (FL) 278 Butabarbital, classification under Controlled
What's New Aspirin, compared with heparin in myocardial Substances Act (U) 184; use in nursing facili-
ty residents (PF) 37
infarction (A) 107
JOURNAL OF PHARMACY TECHNOLOGY Vowume 8 Novemser/Decemser 1992 293
Clintec Launches Ultrapak (WN) 227 Demystifying the Cardiopulmonary Code Team
C-D Clonazepam, use in nursing facility residents Response (A) 151
(PF) 36 Denman, Susan J. (author) Analysis of Adverse
Calcitonin, in hypercalcemia (A) 155 Clonidine, in hypertension (FL) 41; transdermal Effects During Amantadine Prophylaxis in a
Calcium antagonists, advanced formulations form (A) 209 Nursing Home Population (A) 74
(A) 204; importance of time of drug adminis- Clorazepate, use in nursing facility residents Depression, treatment with sertraline (A) 238
tration (A) 193; in hypertension (FL) 41 (PF) 36 DeSimone, Edward M. Il (author) book review,
California State Board of Cluxton, Robert J. jr. (author) Grateful Mec: A 104
Technician Regulations (A) 212 User-Friendly, On-Line Literature Search de Valk, Harold W. (author) Treatment of Se-
Calmar Develops New Design for Child-Resis- System (U) 143 vere Hypercalcemia in Primary Hyper-
tant Closures (WN) 138 Cluysenaer, Onno J.J. (coauthor) see de Valk, parathyroidism with Aminopropylidene
Harold W., 155 Diphosphonate (A) 155
Co-Promotion Agreement for Hespan An- Dextrose, total parenteral nutrition (A) 7
Canafax, Daniel M. (coauthor) see Seifeldin, nounced (WN) 182 DHE-45, in migraine (PF) 133
Raafat Abdel-Aziz, 81 Coal tar preparations, safe in treating dandruff, Diabetes, insulin infusion pumps (A) 252
Cancer, colorectal, combination therapy ap- seborrheic dermatitis, and psoriasis (WN) 43 —" use in nursing facility residents (PF)
proved (WN) 135; strontium-89 reduces Cocaine, in cardiac arrest (A) 153
metastatic bone pain (WN) 224 Codeine, classification under Controlled Sub- sidteen George E. (coauthor) see Sumner,
Captopril, in hypertension (FL) 41; sublingual stances Act (U) 183 Edward D., 119
formulation (A) 208; sustained- and con- Coley, Rebecca M.R. (coauthor) see Hudson, Dideoxyciiidine, see zalcitabine, 225
trolled-release formulations (A) 206 Teresa J., 195 Dillon, Edward C. (author) book review, 237
Carbenicillin, total parenteral nutrition (A) *S Community pharmacists, elderly patients (A) Diltiazem, in hypertension (FL) 41; sustained-
Cardiac drugs, formulations (A) 203 119; use of reference sources (A) 30 release formulation (A) 205; topical adminis-
Cardiopulmonary resuscitation, pharmacist in- Community Pharmacy Practice and an Aging tration (A) 209
volvement (A) 151; providing pharmaceuti- Population (A) 119 Diphenhydramine, use in nursing facility resi-
cal care (E) 145 Compatibility, with total parenteral nutrition dents (PF) 36
Carteolol, in hypertension (FL) 41 (A) 15 automated system introduced
Catheter sepsis, total parenteral nutrition (A) Competency, maintained through self-evalua- (WN) 93; medications available through
12 tion (A) 78; technicians (A) 23 Sears catalog (WN) 281; robotic system initi-
Cefamandole, total parenteral nutrition (A) 16 Complete Headache Program on Videotape ated (PF) 216
Cefazolin, total parenteral nutrition (A) 16 (WN) 282 Disposable Splash Visor (WN) 282
Cefoperazone, total parenteral nutrition (A) 16 Compliance, pediatric patients (A) 158; versus Diuretics, in hypertension (FL) 41
Cefotaxime, prescribing (A) 27; total parenteral adherence (A) 242 Dopamine, in cardiac arrest (A) 153; total par-
nutrition (A) 16 Compliance Issues and Ext Prepa- enteral nutrition (A) 16
Cefoxitin, total parenteral nutrition (A) 16 ration of Medication for Pediatric Patients (A) Drug administration, contamination of ADD-
Cefsulodin, total parenteral nutrition (A) 16 158 Vantage admixtures (A) 195; importance of
Ceftazidime, prescribing (A) 27; total parenteral Compounding, FDA response to JCPP member time of drug administration in cardiac pa-
nutrition (A) 16 organizations (PF) 275; pediatric patients (A) tients (A) 191; pediatric patients (A) 158;
Ceftriaxone, prescribing (A) 27; total parenteral 158; pharmacists’ rights and responsibilities pharmacy’s responsibility (E) 185; total par-
nutrition (A) 16 (PF) 87 enteral nutrition (A) 6
Cefuroxime, total parenteral nutrition (A) 16 Compounding and Patient Counseling: Pharma- Drug Administration Is Pharmacy’s Responsibili-
Cephalosporins, compatibility with total par- cists’ Rights and Responsibilities (PF) 87 ty (E) 185
enteral nutrition (A) 15; prescribing (A) 27 Continuing education, PharmaCE, order form, Drug delivery, advanced cardiac formulations
Cephalothin, total parenteral nutrition (A) 16 47,95, 141, 173, 229, 285, test questions, 46, (A) 203; new enteral feeding device (WN)
Cephapirin, total parenteral nutrition (A) 16 94, 140, 172, 228, 284 227; nicotine patch marketed (WN) 45; volu-
Chandrasekar, Pranatharthi (author) book re- Controlled Substances Explained (U) 183 metric pump/controller available (WN) 226;
view, 149 Cornish, Laura A. (coauthor) see Bleske, Barry wearable pain-control device developed
Chemotherapeutic Combination Approved for E., 191 (WN) 136
Advanced Colorectal Cancer (WN) 135 Coronary artery disease, importance of time of Drug development (A) 164
Chiropractic doctors, offered hospital access drug administration (A) 191 Drug information, electronic medical reference
(WN) 181 Counseling, environmental factors (A) 242; book (WN) 139; Grateful Med (U) 143; medi-
Chloral hydrate, use in nursing facility resi- pharmacist responsibilities (PF) 87, (NP) 102 cal terms (WN) 45; sources, general (U) 48,
dents (PF) 36 Crime (NP) 102 96, used by Louisiana community pharma-
Chlorambucil, for chronic lymphocytic Cure First Aid Needs with the Cube (WN) 282 cists (A) 30
leukemia (FL) 278 Cyclophosphamide, for acute lymphocytic Drug Information Sources Used by Community
Chloramphenicol, total parenteral nutrition (A) leukemia (FL) 278; for chronic lymphocytic Pharmacists in Louisiana: A Preliminary Study
16 leukemia (FL) 278; total parenteral nutrition (A) 30
Chlordiazepoxide, use in nursing facility resi- (A) 15 Drugs That Treat High Blood Pressure (FL) 41
dents (PF) 36 Cyclosporine, cost and effectiveness in im- Durand, Ronald P. (coauthor) see Sumner, Ed-
Chlorothiazide, in hypertension (FL) 41 munosuppression (A) 81 ward D., 119
ine, use in nursing facility resi- Cytarabine, for acute lymphocytic leukemia
dents (PF) 37 (FL) 278; for acute myelogenous leukemia
ixene, use in nursing facility resi- (FL) 277; total parenteral nutrition (A) 15 E-F
dents (PF) 37 Cytotoxic agents, hanJling (A) 59; report on
Chlorthalidone, in hypertension (FL) 41 National Study Commission on Cytoxic Ex-
Cholestyramine, bar formulation (A) 207 posure (A) 56 Editorials, Gonzalez, Edgar R., Providing Phar-
Cimetidine, total parenteral nutrition (A) 14 Dandruff, safe treatments found (WN) 43 maceutical Care During Cardiopulmonary
Circadian rhythym, influence on drug therapy Daunorubicin, for acute myelogenous leukemia Resuscitation, 145; Whitney, Harvey A.K. Jr.,
(A) 191 (FL) 278 Drug Administration is Pharmacy’s Respon-
Clarithromycin, available (WN) 44 ddC, see zalcitabine, 225 sibility 185; Government Description of Tech-
Clear Away Plantar Cushions as It Heals Plantar Decontamination of a Biological Safety Cabinet nicians 49; Pharmacy’s Version of “The Wiz-
Warts (WN) 139 (U) 231 ard of Oz” 97; The Pharmacist-Technician
Cleary, John D. (author) Impact of Pharmaceu- Decubitus ulcers, NPUAP guidelines released Gap: Is TheOrnee a nd Who Cares? 1; Phar-
tical Sales Representatives on Physician An- (PF) 174 macy Morality: I. Choosing When to Die 233
tibiotic Prescribing (A) 27 Delivery, insulin infusion pumps (A) 252; pre- Eiland, Sallie A. (coauthor) see Allan, Elizabeth
Clindamycin, total parenteral nutrition (A) 16 filled syringe (WN) 281 L., 242
294 JOURNAL OF PHARMACY TECHNOLOGY Vowume 8 Novemser/Decemser 1992
INDEx TO VoLUME 8
Electrolytes, total parenteral nutrition (A) 10 Gentamicin, total parenteral nutrition (A) 16 imipenem, total = nutrition (A) 16
Enalapril, in hypertension (FL) 41 Geriatrics, community pharmacy practice (A) egimens Following
Enteral therapy, videotaped program available 119; participation in medicine review pro- Renal Transplantation: Cownta ndEE ff ectiveness
(WN) 283 gram (WN) 135; substance abuse (A) 65 Analyses (A) 81
, in cardiac arrest (A) 153 Globulin, antilymphocytic, cost and effective- Impact of a Multidisciplinary, Collaborative Ap-
Erstad, Brian L. (coauthor) see Gales, Barry J., ness in immunosuppression (A) 81 proach to Implement and Enforce an Auto-
125 Gloth, F. Michael Ill (coauthor) see Denman, matic Stop Order Policy (A) 20
Erythromycin, total parenteral nutrition (A) 16 Susan J., 74 Impact of Pharmaceutical Sales Representatives
Estazolam, use in nursing facility residents (PF) Gloth, Mark J. (coauthor) see Denman, Susan J., on Physician Antibiotic Prescribing (A) 27
%6 74 Impotence, treatment with nitric oxide (WN)
Ethacrynic acid, in hypertension (FL) 41 Glutethimide, use in nursing facility residents 280
, use in nursing facility residents (PF) 37 Improved Heparin Management During Bypass
(PF) 37 Gonzalez, Edgar R. (author) Providing Pharma- Surgery and PTCA (WN) 182
Famotidine, total parenteral nutrition (A) 14 ceutical Care During Cardiopulmonary Re- Infusions, national infusion therapy association
Fat emulsions, total parenteral nutrition (A) 9 suscitation (E) 145 formed (PF) 130
Federal regulations, drug safety surveillance (A) Government Description of Technicians (E) 49 Insulin, infusion pumps (A) 252; total parenter-
165 Grateful Med: A User-Friendly, On-Line Litera- al nutrition (A) 14
Fentanyl, in cardiac arrest (A) 153 ture Search System (U) 143 Interferon Alfa-2b for Chronic Hepatitis (WN)
Finasteride, approved for benign prostatic hy- Guanabenz, in hypertension (FL) 41 225
perplasia (WN) 226 Guanadrel, in hypertension (FL) 41 Isoproterenol, total parenteral nutrition (A) 16
Finucane, Thomas E. (coauthor) see Denman, Guanethidine, in hypertension (FL) 41 Issues in Cont Drug Delivery, Part V:
Susan J., 74 Guanfacine, in hypertension (FL) 41 Total Parenteral Nutrition (A) 6; Part Vi: Ad-
First aid, new kit marketed (WN) 282 Guar gum, diet pills removed from market vanced Cardiac Drug Formulations (A) 203
First lowa PCT Examination Given (PF) 174 (WN) 135 Ivy's “Poison” May Have Met Its Match (WN)
First National Brown Bag Medicine Review Pro- = — Roy (coauthor) see Pena, 180
gram (WN) 135 Veronica,2 0 Joint Commission of Pharmacy Practitioners, re-
First National Infusion Therapy Association Es- Halazepam, use in nursing facility residents sponse from FDA about compounding (PF)
tablished (PF) 130 (PF) 36 275
First One-Tablet, Once-a-Day, Broad-Spectrum Halcion Update (WN) 180 journal of Pharmacy Technology, author guide-
Quinolone (WN) 135 , use in nursing facility residents lines JF-ifc, MA-ifc, MJ-ifc, JA-ifc, SO-ife, ND-
Five Ingredients Found Safe and Effective for (PF) 37 ifc; reprints, columns, opinions, and stan-
Dandruff (WN) 43 Headaches, videotaped educational program dards MA-ibc, MJ-ibc, JA-ibc, SO-ibe, major
Fludarabine, for chronic lymphocytic leukemia offered (WN) 282; see also migraines articles JF-ibc, ND-ibc; results of reader sur-
(FL) 278 Heparin, in cardiac arrest (A) 153; in throm- vey (E) 1; subscription order form, 2, 51, 99,
Fluoride, level in tap water (WN) 180 bolytic therapy (A) 105; management during 146, 186, 234
Fluorouracil, combination therapy approved bypass surgery (WN) 182; sodium, total par- Kanamycin, total parenteral nutrition (A) 16
for colorectal cancer (WN) 135; total par- enteral nutrition (A) 14 Kidney cancer, aldesleukin licensed (FL) 218
enteral nutrition (A) 15 Hepatitis, B, recombinant interferon alfa-2b ap-
Fluoxetine, compared with sertraline (A) 238 proved (WN) 225; screening for B and C
Fluphenazine, use in nursing facility residents (WN) 280
L-M
(PF) 37 Heroin, classification under Controlled Sub-
Flurazepam, use in nursing facility residents stances Act (U) 183
(PF) 36 High Schoolers’ Practice Risky Business (FL) 220 Labeling, FDA requirements (A) 198
Fluvoxamine, compared with sertraline (A) 238 Hilleman, Daniel E. (author) Issues in Contem- Labetalol, in hypertension (FL) 41
Food and Drug Administration, advisory com- porary Drug Delivery. Part VI: Advanced Lancaster, Carol J. (coauthor) see Sumner, Ed-
mittee discusses triazolam (WN) 180; ap- Cardiac Drug Formulations (A) 203 ward D., 78, 119
proves finasteride (WN) 226; approves Histamine, Antagonists, total parenteral nutri- Letters, Technician Schools and Training Pro-
histrelin (WN) 138; approves marketing of tion (A) 14 grams, Shecter J., 149
pamidronate disodium (WN) 44; approves Histrelin for Precocious Puberty (WN) 138 Leucovorin, combination therapy approved for
recombinant interferon alfa-2b (WN) 225; la- itals Adding Doctors of Chiropractic to colorectal cancer (WN) 135
beling requirements (A) 198; lack of regula- Their Staffs (WN) 181 Leukemia, treatment (FL) 277
tion of buyers clubs (FL) 219; licenses Hotta, S. Steven (author) Reassessment of Ex- Levarterenol bitartrate, total parenteral nutri-
aldesleukin (FL) 218; patient restraint devices ternal Insulin Infusion Pumps (A) 252 tion (A) 16
(WN) 224; requests manufacturers of an- How Much Fluoride Is in Your Water? (WN) Liability, pharmacist evaluation of suspicious
giotensin-converting enzyme inhibitors to 180 prescriptions (FL) 39
notify physicians of risks to pregnant wom- Hudson, Teresa J. (author) Potential for Micro- Lidocaine, in cardiac arrest (A) 153; total par-
en (FL) 178; responds to JCPP member orga- bial Contamination of ADD-Vantage Admix- enteral nutrition (A) 16
nizations about compounding of prescrip- tures (A) 195 Light-Stability Test Chamber Introduced (WN)
tion medications (PF) 275; takes guar gum Hydralazine, in hypertension (FL) 41 227
diet pills off market (WN) 135; terfenadine Hydrochloric acid, total parenteral nutrition (A) Lilly Launches Lorabid (WN) 282
warning (PF) 216; 566C80 given treatment 14 Lisinopril, in hypertension (FL) 41
IND status (WN) 43 Hydrochlorothiazide, in hypertension (FL) 41 Literature, From the, Achieving Teamwork Be-
Fuller, Matthew A. (coauthor) see Tolbert, San- Hydrocortisone sodium succinate, total par- tween Pharmacists and Technicians: A Phar-
dra R., 238 enteral nutrition (A) 14 macist’s Perspective, McFarland H.M., Amer-
Furosemide, in hypertension (FL) 41; total par- Hydroflumethiazide, in hypertension (FL) 41 ican Journal ofH ospital Pharmacy (1992) 217;
enteral nutrition (A) 16 Hydromorphone, total parenteral nutrition (A) Are You Tapping the Potential of the Non-
15 physician Prescriber?, Huston P., Medical
Hydroxyurea, for chronic myelogenous Marketing and Media (1991) 134; Career Lad-
leukemia (FL) 278 ders: Panacea or Plague?, Crouch J., Hospital
G-K Hydroxyzine, use in nursing facility residents Pharmacy Times (1992) 177; Certain Hyper-
(PF) 36 tension Drugs Dangerous for Pregnant
Gales, Barry J. (author) Albumin Audit Results Hypercalcemia, of malignancy, marketing of Women, FDA Consumer (1992) 178; Despite
and Guidelines for Use (A) 125 pamidronate disodium approved (WN) 44 New Clues Alzheimer’s Mystery Remains
Gallelli, joseph F. (author) A Report on the Na- Hyperparathyroidism, treatment with amino- Unsolved, Flieger K., FDA Consumer (1992)
tional Commission on Cytotoxic Exposure propylidene diphosphonate (A) i55 175; Drugs That Treat High Blood Pressure,
(A) 55 Hypertension, treatment (FL) 41 FDA Consumer (1991) 41; FDA Licenses Kid-
JOURNAL OF PHARMACY TECHNOLOGY Votuume 8 Novemser/Decemser 1992 295
ney Cancer Treatment, FDA Consumer (1992) Morphine, in cardiac arrest (A) 153; total par- Orphan drugs, .-threonine (WN) 280
218; High Schoolers’ Practice Risky Business, enteral nutrition (A) 15 Oxacillin, total parenteral nutrition (A) 16
FDA Consumer (1992) 220; New Drugs, New Moxalactam, total parenteral nutrition (A) 16 Oxazepam, use in nursing facility residents
Alternatives: Understanding Leukemia, Myocardial infarction, laser for clogged arteries (PF) 37
Mayfield E., FDA Consumer (1992) 277; Notes (WN) 136; use of heparin (A) 105 Oxygen, in cardiac arrest (A) 152
from the Underground, Laskoski G., Ameri-
can Druggist (1992) 218; Panic Disorder—A
National Problem, A Federal Response, N-O P-Q
Leshner A.1., Public Health Reports (1992) 89;
Patient Goes Berserk, Rx Ipsa Loquitur (1992)
89; Pharmacy-Based Medication Administra- Nadolol, in hypertension (FL) 41 Packaging, new child-resistant closures devel-
oped (WN) 138
tion Program, Silver LA., Lupano C.P., and Nafcillin, total parenteral nutrition (A) 16
Sandler A.L., American Journal of Hospital Nation’s First Pharmacy Robot (PF) 216 Pagliaro, Ann M. (author) The Phenomenon of
Pharmacy (1992) 278; Technician Economic National Association of Boards of Pharmacy, Substance Abuse Among the Elderly, Part II:
Survey, Journal Michigan Pharmacist (1992) 88; Scope of Pharmacy Practice Project (PF) 38 The Mega-Interative Model (A) 111; (coau-
The Biochemistry of Migraine Headaches, National Pharmaceutical Association, new lead- thor) see Pagliaro, Louis A., 65
Larkin M., Priorities (1992) 131; The Pharma- ership direction (PF) 276 Pagliaro, Louis A. (author) The Phenomenon of
cist’s Responsibility to Evaluate Suspicious National Pressure Ulcer Advisory Panel, releas- Substance Abuse Among the Elderly: Part I
Prescriptions, Brushwood D.B., and Carlson es new guideline (PF) 174 (A) 65; (coauthor) see Pagliaro, Ann M., 111
).J., Food, Drug, and Cosmetic Journal (1991) 39 Nationwide Screening Program for Hepatitis B Pain, nead (WN) 282; management, book re-
Lomefloxacin, approved for marketing (WN) and C (WN) 280 view (NP) 237, guideline (WN) 92; new de-
135 Neoplasia, link to oral contraceptive use (NP) vice permits aggressive use of painkillers
Loracarbef, available in the US (WN) 282 189 (WN) 136; strontium-89 reduces metastatic
Lorazepam, use in nursing facility residents New Acute Pain Management Guidelines (WN) bone pain (WN) 224
(PF) 36 92 Palm-Sized Electronic Medical Speller and
Loxapine, use in nursing facility residents (PF) New AIDS Drug Licensed (WN) 225 Word Verifier (WN) 45
37 New Arizona Pharmacy Certified Technicians Pamidronate, given marketing approval (WN)
LSD, see lysergic acid diethylamide (PF) 87 At
i-threonine, receives orphan drug designation New Consumers’ Guide to Obtaining Medical Panic Disorder—A National Problem, A Federal
(WN) 280 Records (WN) 281 Response (FL) 89
Lysergic acid diethylamide, classification (U) 183 New Drug Device Permits More Aggressive Use Paraldehyde, use in nursing facility residents
Magnesium Sulfate Delivery Simplified with Pre- of Painkillers (WN) 136 (PF) 37
mixed Solution (WN) 182 New Drug for Life-Threatening Cancer Compli- Patient Goes Berserk (FL) 89
Mahajan, Puneet (coauthor) see Rae, cation (WN) 44 Patient Treatment Adherence: Facility Design
Charlesworth E., 30 New Drug Significantly Reduces Risk of Stroke and Counseling Skills (A) 242
Mauro, Vincent F. (coauthor) see Stoneman, (WN) 137 Pediatrics, dosing (A) 158
David K., 105 New Electronic Medical Reference Book (WN) Pena, Veronica (author) Impact of a Multidisci-
Mecamylamine, in hypertension (FL) 41 139 plinary, Collaborative Approach to Imple-
Medical records, patient access (WN) 281 New FDA Guidelines on Patient Restraint De- ment and Enforce an Automatic Stop Order
Mega-Interactive Model of Substance Abuse vices (WN) 224 Policy (A) 20
Among the Elderly (A) 111 New Laser Device for Clogged Arteries (WN) 136 Penbutolol, in hypertension (FL) 41
Meperidine, classification under Controlled New Liquid Medications from Roxane (WN) 283 Penicillin, total parenteral nutrition (A) 15
Substances Act (U) 183; total parenteral nu- New Peak-Flow Meters for Asthmatic Patients Pentobarbital, use in nursing facility residents
trition, 15 (WN) 93 (PF) 37
te, use in nursing facility residents New Publication Examines Pharmaceutical In- Pentostatin, for hairy cell leukemia (FL) 278
(PF) 37 dustry Contributions (WN) 180 Perphenazine, use in nursing facility residents
Mesoridazine, use in nursing facility residents New Volumetric Pump/Controller from IMED (PF) 37
(PF) 37 (WN) 226 PharmaCE, order form, 47, 95, 141, 173, 229, 285;
Methicillin, total parenteral nutrition (A) 16 Nicardipine, in hypertension (FL) 41 test questions, 46, 94, 140, 172, 228, 284
Methotrexate, total parenteral nutrition (A) 15 Nickel, Ronald O. (coauthor) see Sumner, Ed- Pharmacists, achieving teamwork with techni-
Methprylon, use in nursing facility residents ward D., 78 cians (FL) 217; career ladders (FL) 177; com-
(PF) 37 Nicotine, delivery (NP) 236 munity, use of reference sources (A) 30; en-
Methyclothiazide, in hypertension (FL) 41 Nicotine Patch for Smoking Cessation (WN) 45 try-level PharmD degree (PF) 174; salaries
Methyldopa, in hypertension (FL) 41 Nifedipine, immediate-release formulation (A) (PF) 37; suspicious prescriptions (FL) 39;
Methyldopate hydrochloride, total parenteral 205; in hypertension (FL) 41; sublingual form technician potential unrecognized (E) 1
nutrition (A) 16 (A) 208 Pharmacist’s Responsibility to Evaluate Suspi-
Methylphenidate, classification under Con- Nitrates, importance of time of drug adminis- cious Prescriptions, The (FL) 39
trolled Substances Act (U) 183 tration (A) 193 Pharmacist-Technician Gap: Is There One and
Methylprednisolone, total parenteral nutrition Nitric oxide, for treating impotence (WN) 280 Who Cares?, The (E) 1
(A) 14 Nitroglycerin, in cardiac arrest (A) 153; sublin- Pharmacy Focus, ACA Endorses Joint State-
Metoclopramide, oral liquid form available gual and buccal formulations (A) 207; trans- ment on Entry-Level PharmD Degree 174;
(WN) 283; total parenteral nutrition (A) 14 dermal formulation (A) 208 APhA Comments on Seldane Warning 216;
Metolazone, in hypertension (FL) 41 Nizatidine, total parenteral nutrition (A) 14 APhA Considers Technician Recognition
Metoprolol, in hypertension (FL) 41; topical ad- Notes from the Underground (FL) 218 130; APhA Foundation Prepares to Meet
ministration (A) 209 NPhA Charts New Professional Course (PF) 276 New Challenges 174; APhA to Conduct
Metronidazole, in bacterial vaginosis (WN) 181 NPUAP Endorses New Guideline for Prevention Study on the Underutilization of Medicines
Mezlocillin, total parenteral nutrition (A) 16 of Pressure Ulcers (PF) 174 130; APhA’s Salary Survey Analyzes Phar-
Migraines, biochemistry (FL) 131; see also Nutrition, total parenteral (A) 6 macists’ Compensation 37; Are Regulations
headaches Nystatin, oral liquid form available (WN) 283 that Sanction Techs Checking Techs Coming
Minoxidil, in hypertension (FL) 41 i ive disorder, treatment with Soon? 276; British Association of Pharmacy
Mithramycin, in hypercalcemia (A) 155 sertraline (A) 240 Technicians Annual Conference Highlights
Mohler, Pamela A. (author) Issues in Contem- Octreotide, total parenteral nutrition (A) 14 215; California Technicians Get Final Legal
porary Drug Delivery. Part V: Total Par- Origins and Goals of the British Association of Approval to Become Registered 275; Canadi-
enteral Nutrition (A) 6 Pharmacy Technicians (PF) 215 an Society of Hospital Pharmacists Resolu-
i , use in nursing facility residents Orphan Drug Status Granted for Spasticity tion 87; Compounding and Patient Counsel-
(PF) 37 Product (WN) 280 ing: Pharmacists’ Rights and Responsibilities
296 JOURNAL OF PHARMACY TECHNOLOGY Votume 8 Novemser/Decemser 1992
INDEX TO VOLUME 8
87; FDA Responds to JCPP Member Organi- Protamine, management during bypass Ramipril, in hypertension (FL) 41
zations About Compounding of Prescription surgery (WN) 182 Ranitidine, total parenteral nutrition (A) 14
Medications 275; First lowa PCT Examina- Providing Pharmaceutical Care During Car- Rapid AIDS Test Introduced (WN) 182
tion Given 174; First National Infusion Ther- diopulmonary Resuscitation (A) 145 Rappaport, Harvey M. (coauthor) see Rae,
apy Associatici: Established 130; Nation’s Psoriasis, safe treatments found (WN) 43 Charlesworth E., 30
First Pharmacy Robot 216; New Arizona Publications, New, Counseling Patients on Their Rauwolfia alkaloids, in hypertension (FL) 41
Pharmacy Certified Technicians 87; NPhA Medications: One of the Principal Responsibili- Reassessment of External Insulin Infusion Pumps
Charts New Professional Course 276; ties of the Health Care Practitioner, Karig A.W., (A) 252
NPUAP Endorses New Guideline for Pre- Hartshorn E.A. 102; New Developments in Report on the National Commission on Cytotox-
vention of Pressure Ulcers 174; Origins and Nicotine-Delivery Systems, Henningfield J.E., ic Exposure,A (A) 55
Goals of the British Association of Pharmacy Stitzer M.L. 236; Nicotine Replacement: A Criti- Restraints, new FDA guidelines (WN) 224
Technicians 215; Project HOPE Continues cal Evaluation, Pomerleau O.F., Pomerleau Richard S. Berman, Founder and President
Medical Supply Effort for Former USSR 87; CS. 236; Oral Contraceptives and Neoplasia, Emeritus of ASCP, Dies (PF) 275
Richard S. Berman, Founder and President World Health Organization) 189; Pharmaceu- Roca, Robert P. (coauthor) see Denman, Susan.
Emeritus of ASCP, Dies 275; Scope of Phar- tical Drug Crime: Analysis and Prevention, Lan- J., 74
macy Practice Project Receives Grant 38; caster K. 102; Physician's 1992 Drug Handbook, Rodgers, Paul E. (coauthor) see Brumbaugh,
South Carolina to Give Technician Certifica- Hamilton H. 149; Rheumatic Diseases, World Brenda M., 231
tion Examination 36; Special Report: Draft of Health Organization 189; The Management of Role of Heparin in the ThrombolTyretatimcen t
HCFA Nursing Facility Guidelines on Un- Acute Pain, Park G., Fulton B. 237; USAN and of Acute Myocardial Infarction, The (A) 105
necessary Drugs 36; Technician Standards the USP Dictionary of Drug Names, 1992, Safety, disposable visor (WN) 282; product la-
Proposed 87; Who Comes to the APhA An- Fleeger C.A. 4; WHO Model Prescribing Infor- beling (A) 198; surveillance (A) 162
nual Meeting? 38 mation: Drugs Used in Mycobacterial Diseases Salicylic acid, safe in treating dandruff, sebor-
Pharmacy Technician Competency. Part IV: At- 1991, World Health Organization 54 rheic dermatitis, and psoriasis (WN) 43
titudes (A) 23 Pyrithione zinc, safe in treating dandruff and Schell, Kenneth H. (author) Compliance Issues
PharVersmion aof tche “yWiz’ard sof Oz” (E)9 7 seborrheic dermatitis (WN) 43 and Extemporaneous Preparation of Medica-
Phenobarbital, classification under Controlled Quazepam, use in nursing facility residents tions for Pediatric Patients (A) 158
Substances Act (U) 183; use in nursing facili- (PF) 36 Scientist Describes Biochemical Trigger for Pro-
ty residents (PF) 37 Quinethazone, in hypertension (FL) 41 duction of Nitric Oxide (WN) 280
Phenomenon of Substance Abuse Among the El- Quotes, Historical, ASHP, NARD, APhA Consid- Scope of Pharmacy Practice Project Receives
derly, Part 1, The (A) 65; Part Il: The Mega-in- er Technicians, Johnson W.H. Jr., Technicians: Grant (PF) 38
teractive Model, (A) 111 Pharmacy’s ‘Hot Potatoes’ (1968) 251; Commu- Sears Catalog Offers Medications (WN) 281
Phenylephrine, in cardiac arrest (A) 153 nity Practice Roles, Trygstad V.O., Meeting Seborrheic dermatitis, safe treatments found
Pimozide, use in nursing facility residents (PF) 37 the Challenge of Change in Pharmacy (1967) (WN) 43
Pindolol, in hypertension (FL) 41 157; C ing Admixtures—Whose Secobarbital, classification under Controlled
Piperacillin, total parenteral nutrition (A) 16 Role?, Francke D.E., American Journal of Hos- Substances Act (U) 184; use in nursing facili-
Plasma, volume expander marketed (WN) 182 pital Pharmacy (1965) 197; Future of Pharma- ty residents (PF) 37
Pneumonia, community-acquired, clar- cy—MD’s View, Johnson W.H. Jr., A Doctor Seifeldin, Raafat Abdel-Aziz (author) Immuno-
ithromycin available (WN) 44; Pneumocystis Diagnoses Pharmacy’s Future (1969) 258; Gov- suppressive Drug Regimens Following Re-
carinii, 566C80 receives treatment IND status ernment’s USPHS Position on Technicians, nal Transplantation: Cost and Effectiveness
(WN) 43 Johnson W.H. Jr., Government . . . the Con- Analyses (A) 81
Poison ivy, anti-ivy agent licensed (WN) 180 cerned Onlooker (1968) 291; Machines for Selenium sulfide, safe in treating dandruff and
Policies, automatic stop order (A) 20; pharma- Pharmacists, Faudman A., Meeting the Chal- seborrheic dermatitis (WN) 43
cist evaluation of suspicious prescriptions lenge of Change in Pharmacy (1967) 38, Salis- Serotonin, sertraline in treatment of depression
(FL) 39 bury R., The Pharmacist’s Role in Optimum Pa- (A) 238
Polymyxin, total parenteral nutrition (A) 16 tieCarne (t196 5) 41; Manpower Predictions, Sertraline: A New Serotonin Reuptake Inhibitor
Polythiazide, in hypertension (FL) 41 Oddis J.A., Meeting the Challenge of —— in (A) 238
Potential for Microbial Contamination of ADD- Pharmacy (1967) 167; Nonpharmacist Pharma- Shaughnessy, Allen F. (author) book review, 237
Vantage Admixtures (A) 195 cy Owners, Salisbury R., TheP harmacistR’osl e Shea, Michael J. (coauthor) see Bleske, Barry E.,
Prazepam, use in nursing facility residents (PF) in Optimum Patient Care (1965) 154; Nurse’s 191
36 View of Drug Administration by Pharmacy, Shecter, jeff (author) Technician Schools and
Prazosin, in hypertension (FL) 41 Gregorich M.R., American Journal of Hospital Training Programs (L) 149
Prednisolone, for chronic lymphocytic leukemia Pharmacy (1971) 220; Pharmacist’s View of Shimp, Leslie A. (coauthor) see Bleske, Barry E.,
(FL) 278 Drug Administration by Pharmacy, Berry 191
Prednisone, cost and effectiveness in immuno- C.C., American Journal ofH ospital Pharmacy Sodium bicarbonate, in cardiac arrest (A) 153;
suppression (A) 81; for acute lymphocytic (1970) 194; Specialtiesi n Pharmacy, Oddis total parenteral nutrition (A) 14
leukemia (FL) 278; for chronic lymphocytic J.A., Meeting the Chon oofCf hC ahnagney ii n Phar- Sodium nitroprusside, in cardiac arrest (A) 153
leukemia (FL) 278 macy (1967) 35; Technician Dispensing, Miller Sorting Through the Sources (U) 48; Part II, 96
ing, geriatric pharmacy (A) 120; impact W.A., Drug Intelligence and Clinical Pharmacy rnsC arolina to Give Technician Certification
of pharmaceutical sales representatives (A) (1977) 178; Technician Education—Whose Examination (PF) 36
27; nonphysicians (PF) 133; pharmacist re- Role?, Johnson W.H. Jr., Educators Discuss Spastic paraparesis, L-threonine received or-
sponsibility to evaluate (FL) 39 Technicians—apprehensively! (1968) 273; Tech- phan drug status (WN) 280
Primer of Drug Safety SurveillancAe: ,A n Indus- nician Education, Miller W.A., Drug Intelli- Special Report: Draft of HCFA Nursing Facility
try Perspective, Part I: Information Flow, gence and Clinical Pharmacy (1977) 64; Tech- Guidelines on Unnecessary Drugs (PF) 36
New Drug and Federal Regula- nologist as Assistant for Pharmacist, Whitney Spironolactone, in hypertension (FL) 41
tions (A) 162; Part Il: Product Labeling and H.AK. Jr., The Pharmacy Technologist: a New Stability, light-stability test chamber introduced
Product Knowledge (A) 198; Part Ill: Manag- Assistant for the Clinical Pharmacist (1974) 283; (WN) 227
ing Adverse-Event Data (A) 259 Third Class of Drugs, Hager G.P., The Pharma- Steroids, anabolic, classification under Con-
Procainamide, in cardiac arrest (A) 153; sus- cist’s Role in Optimum Patient Care (1965) 134 trolled Substances Act (U) 183
tained- and immediate-release formulations Stoneman, David K. (author) The Role of Hep-
(A) 206 arin in the Thrombolytic Treatment of Acute
Project HOPE Continues Medical Supply Effort Myocardial Infarction (A) 105
for Former USSR (PF) 88 R-S Storage, automated system introduced (WN) 93
Promazine, use in nursing facility residents (PF) Streptokinase, with heparin in myocardial in-
37 Rae, Charlesworth E. (author) Drug Informa- farction (A) 108
, in hypertension (FL) 41; sustained- tion Sources Used by Community Pharma- Strontium-89 Effective in Reducing Metastatic
release formulation (A) 206 cists in Louisiana (A) 30 Bone Pain (WN) 224
JOURNAL OF PHARMACY TECHNOLOGY Votuume 8 Novemser/DecemBer 1992 297
Substance abuse, elderly (A) 65, 111 Triazolam, safety and efficacy discussed by nificantly Reduces Risk of Stroke 137; New
Suchanek-Hudmon, Karen L. (coauthor) see Al- FDA (WN) 180; use in nursing facility resi- Electronic Medical Reference Book 139; New
lan, Elizabeth L., 242 dents (PF) 37 FDA Guidelines on Patient Restraint Devices
Sulfur, safe in treating dandruff (WN) 43 Trifluoperazine, use in nursing facility residents 224; New Laser Device for Clogged Arteries
Sumatriptan, in migraine (PF) 133 (PF) 37 136; New Liquid Medications from Roxane
Sumner, Edward D. (author) Community Phar- Two-Part Enteral Therapy Video Program from 283; New Peak-Flow Meters for Asthmatic
macy Practice and an Aging Population (A) ASCP (WN) 283 Patients 93; New Publication Examines Phar-
119; Using Self-Evaluation to Maintain Com- Universal Prefilled Syringe System (WN) 281 maceutical Industry Contributions 180; New
petence (A) 78 Updating Your Skills, Controlled Substances Ex- Volumetric Pump/Controller from IMED
plained 183; Decontamination of a Biological 226; Nicotine Patch for Smoking Cessation
Safety Cabinet 231; Grateful Med: A User- 45; Orphan Drug Status Granted for Spastici-
Friendly, On-Line Literature Search System ty Product 280; Palm-Sized Electronic Medi-
T-V 143; Sorting Through the Sources 48, Part II cal Speller and Word Verifier 45; Rapid
96; What Kind of Anemia is That? 290 AIDS Test Licensed 182; Scientist Describes
Tacrine, use in Alzheimer’s (FL) 176 Using Self-Evaluation to Maintain Competence Biochemical Trigger for Production of Nitric
Technician Economic Survey (FL) 88 (A) 78 Oxide 280; Sears Catalog Offers Medications
Technician Education and Training Programs: Vancomycin, total parenteral nutrition (A) 16 281; Strontium-89 Effective in Reducing
An Addendum (A) 168 Variability in Drug Administration Times Among Metastatic Bone Pain 224; Therapy for Bacte-
Technician Schools and Training Programs (L) Patients with Coronary Artery Disease (A) rial Vaginosis Submitted for Review 181; To-
149 191 bacco Linked to 23 Percent of Oregon Deaths
Technician Standards Proposed (PF) 87 Vasodilators, in hypertension (FL) 41 in 1989 224; Two-Part Enteral Therapy Video
Technicians, achieving teamwork with phar- Verapamil, in cardiac arrest (A) 153; in hyper- Program from ASCP 283; Universal Prefilled
macists (FL) 217; attitudes (A) 23; California tension (FL) 41; sustained-release formula- Syringe System 281; 566C80 Receives Treat-
proposed regulations (A) 212; certification tion (A) 205 ment IND Status for AIDS-Related Use 43
(PF) 36; certified in Arizona (PF) 87; checking Vincristine, for acute lymphocytic leukemia Whitney, Harvey A.K. Jr. (author) Drug Admin-
each other’s work (PF) 276; competency (A) (FL) 278 istration is Pharmacy’s Responsibility (E)
23; compounding of pediatric formulations Vitamins, total parenteral nutrition (A) 10 185; Government Description of Technicians
(A) 161; economic survey (FL) 88; govern- (E) 49; Pharmacy’s Version of the “Wizard of
ment description (E) 49; lowa certification ex- Oz” (E) 97; The Pharmacist-Technician Gap:
amination administered (PF) 174; potential Is There One and Who Cares? (E) 1; Pharma-
unrecognized by pharmacists (E) 1; recogni- W-Z cy Morality: I. Choosing When to Die 233
tion by APhA (PF) 130; registered in Califor- Who Comes to the APhA Annual Meeting? (PF)
nia (PF) 275; standards proposed (PF) 87; Warts, new cushion heals plantar warts (WN) 38
training, on-the job vs. formal (A) 23, pro- 139 Wilkie, Ralph M. (coauthor) see Sumner, Ed-
grams (L) 149, (A) 168 Wertheimer, Albert 1. (coauthor) see Seifeldin, ward D., 78
Temazepam, use in nursing facility residents Raafat Abdel-Aziz, 81; see Thuo, H. Michael, Zalcitabine, granted FDA approval (WN) 225
(PF) 37 23
Terazosin, in hypertension (FL) 41 What Kind of Anemia is That? (U) 290
Terfenadine, APhA comments on FDA warn- What’s New, Abbott to Market New Oral An-
ing (PF) 216 tibiotic 44; ASCP Names Erwin to Receive Numbers
Test Your Knowledge, answers, 42, 91, 142, 179, Archambault Award 43; Automated Medica-
230, 286; questions, 5, 52, 100, 148, 188, 274 tion Storage and Dispensing System 93; Cal- 2CDA, for hairy cell leukemia (FL) 278
Tetracycline, total parenteral nutrition (A) 16 mar Develops New Design for Child-Resis- 566C80 Receives Treatment IND Status for
Theophylline, total parenteral nutrition (A) 16 tant Closures 138; Chemotherapeutic Combi- AIDS-Related Use (WN) 43
Therapy for Bacterial Vaginosis Submitted for nation Approved for Advanced Colorectal
Review (WN) 181 Cancer 135; Clear Away Plantar Cushions as
Thioridazine, use in nursing facility residents It Heals Plantar Warts 139; Clintec Launches
(PF) 37 Ultrapak 227; Complete Headache Program Advertisers
Thiothixene, use in nursing facility residents on Videotape 282; Co-Promotion Agreement
(PF) 37 for Hespan Announced 182; Cure First Aid Association of Pharmacy Technicians, 40th An-
Thomas, David R. (coauthor) see Denman, Su- Needs with the Cube 282; Disposable Splash niversary Study Weekend, 19
san }., 74 Visor 282; FDA Approves Prostate Drug 226; Harvey Whitney Books, books, journals, and
Thornley, Susanne M. (author) book review, FDA Orders Guar Gum Diet Pills Off Market reprints for pharmacy and pharmacothera-
102 135; First National Brown Bag Medicine Re- py, 221, 287; Nutrition Support Handbook, 22,
Thuo, H. Michael (author) Pharmacy Techni- view Program 135; First One-Tablet, Once-a- 139, 146; Pediatric Drug Formulations, 292; The
cian Competency. Part IV: Attitudes (A) 23 Day, Broad-Spectrum Quinolone 135; Five Practice of Pharmacy, 232; Psychotropic Drug
Ticarcillin, total parenteral nutrition (A) 16 Ingredients Found Safe and Effective for Handbook, 118;
Ticlopidine, available in US (WN) 137 Dandruff 43; Halcion Update 180; Histrelin Humber College, 11th annual conference, 171,
Timolol, in hypertension (FL) 41; transdermal for Precocious Puberty 138; Hospitals 211
form (A) 209 Adding Doctors of Chiropractic to Their Midlands Technical College, national confer-
Tissue plasminogen activator, use with heparin Staffs 181; How Much Fluoride Is in Your ence, 124
in myocardial infarction (A) 106 Water? 180; Improved Heparin Management
Tjoeng, Matthieu M. (coauthor) see de Valk, During Bypass Surgery and PTCA 182; Inter-
Harold W., 155 feron Alfa-2B for Chronic Hepatitis 225; Ivy’s Statement of ownership, management, and bimonthly cir-
Tobacco Linked to 23 Percent of Oregon “Poison” May Have Met Its Match 180; culation (6 issues, $64 annually) of the journal of Pharmacy
Technology, publication no. 87551255. Owner: Harvey Whit-
Deaths in 1989 (WN) 224 Light-Stability Test Chamber Introduced 227; ney Books Company. Publisher, editor, and managing edi-
Tobramycin, total parenteral nutrition (A) 16 Lilly Launches Lorabid 282; Magnesium Sul- tor: Harvey A.K. Whitney, Jr. Headquarters of publisher,
Tolbert, Sandra R. (author) Sertraline: A New fate Delivery Simplified with Premixed Solu- owner, and publication: 8044 Montgomery Road, P.O. Box
42696, Cincinnati, OH 45242. Known bondholders, mort-
Serotonin Reuptake Inhibitor (A) 238 tion 182; Nationwide Screening Program for gagees, and other security holders: none. Average no. of
Total parenteral nutrition, coadministration of Hepatitis B and C 280; New Acute Pain copies each issue from October 91 to September 92 and no.
drugs (A) 14 Management Guideline 92; New AIDS Drug of copies of September 92: A. total no. copies printed (net
Treatment of Severe Hypercalcemia in Primary Licensed 225; New Consumer’s Guide to Ob- press run) 1900, 2000; B. paid circulation (1) single copy
sales 0, 0; (2) mail subscription 1253, 967; C. total paid circu-
Hyperparathyroidism taining Medical Records 281; New Drug De- lation 1253, 967; D. free distribution 381, 764; E. total distri-
with Aminopropylidene Diphosphonate (A) vice Permits More Aggressive Use of bution (C + D) 1634, 1731; F. office use, left over, etc. 266,
155 Painkillers 136; New Drug for Life-Threaten- 269; G. total (E + F) 1900, 2000. No. of issues published an-
nually: 6. Date of filing: 28 September 1992. Signed: Harvey
Triamterene, in hypertension (FL) 41 ing Cancer Complication 44; New Drug Sig- A.K. Whitney, Jr., Publisher
298 JOURNAL OF PHARMACY TECHNOLOGY Vouume 8 Novemser/Decemser 1992
iRioes = ee D uty